首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 精神病 > 憂鬱症治療藥物:開發平台評估與到2018年為止的市場預測
產業/市場分類
製藥 (4816)
肥胖症治療 (44)
非專利藥 (129)
疫苗 (181)
神經疾病 (172)
骨頭疾病治療 (37)
動物用醫藥 (17)
處方藥 (156)
規章 (126)
感染疾病 (346)
精神病 (84)
製藥企業 (524)
糖尿病 (191)
癌症 (909)
藥物開發 (1449)
DDS (182)
OTC 非處方藥 (150)
市場調查報告書

憂鬱症治療藥物:開發平台評估與到2018年為止的市場預測

Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018

出版商 GlobalData
出版日期 2011年10月 商品編碼 217929
內容資訊 英文 Pages: 95
價格
US $ 3500 PDF by E-mail (Single user license)
US $ 7000 PDF by E-mail (Site license)
US $ 10500 PDF by E-mail (Global license)


憂鬱症治療藥物:開發平台評估與到2018年為止的市場預測 是由出版商GlobalData在2011年10月所出版的。 這份英文市場調查報告書包含Pages: 95 價格從美金3500起跳。

簡介

本報告提供憂鬱症的治療方法的研究以及開發的最新趨勢調查，進行相關的市場預測，疾病概要及處置法，全球及主要7個國家的市場規模測量與預測(2005-2010年2018年)，競爭結構、臨床實驗進行狀況相關開發平台的評估，同時也提供市場趨勢以及企業相關策略考察，為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 多形性神經動物膠芽腫概要
  • 免疫學
  • 病因及病理學
  • 徵兆與症狀
  • 診斷
  • 治療·管理選擇
  • 本報告內容架構

第3章 市場特徵

  • 市場規模測量:全球(2005-2010年)
  • 市場規模預測:全球(2010-2018年)
  • 市場規模測量:美國(2005-2010年)
  • 市場規模預測:美國(2010-2018年)
  • 市場規模測量:法國(2005-2010年)
  • 市場規模預測:法國(2010-2018年)
  • 市場規模測量:德國(2005-2010年)
  • 市場規模預測:德國(2010-2018年)
  • 市場規模測量:義大利(2005-2010年)
  • 市場規模預測:義大利(2010-2018年)
  • 市場規模測量:西班牙(2005-2010年)
  • 市場規模預測:西班牙(2010-2018年)
  • 市場規模測量:英國(2005-2010年)
  • 市場規模預測:英國(2010-2018年)
  • 市場規模測量:日本(2005-2010年)
  • 市場規模預測:日本(2010-2018年)
  • 市場促進·阻礙因素
  • 影響今後的市場，今後的主要趨勢
  • 機會及未飽和需求
  • 主要的結論

第4章 競爭的環境

  • 概要
    • 策略性競爭企業分析
  • 主要的市售產品簡介
    • 選擇性血清素再回收抑制劑
    • 立普能
    • Viibryd(維拉佐酮)
    • 正腎上腺素再回收抑制劑(SNRI)
    • 千憂解(duloxetine hydrochloride)
    • Pristiq(琥珀酸去甲文拉法辛)
    • Symbyax(Olanzapine/fluoxetine藥物組合劑)
  • 主要的結論

第5章 開發平台評估

  • 概要
  • 策略性開發平台評估
  • 各開發階段平台
    • 階段III管線
    • 階段II管線
    • 階段I管線
    • 前臨床開發平台
    • 技術趨勢分析架構
  • 各行動機制的管線
  • 臨床實驗階段的潛力藥物
  • 有潛力的藥劑的分子簡介
    • Lu AA21004
    • TC-5214
    • AGO178 (agomerachin)
  • 主要的結論

第6章 臨床實驗藍圖

  • 各地區·各國的臨床實驗數(美國·EU5個國家·日本)
  • 各階段臨床實驗數
  • 檢驗各階段臨床實驗數
  • 有潛力的贊助商
  • 參加憂鬱症臨床實驗的前幾名企業

第7章 策略性評估

  • 未來市場競爭方案
  • 的影響向今後的市場競爭

第8章:今後的市場參加企業

  • 簡介
  • 企業簡介
    • Lundbeck A/S
    • Novartis AG
    • AstraZeneca PLC
    • Eli Lilly and Company
    • Targacept Inc

第9章 許可證·合作交易

第10章 附錄

圖表一覽

目錄

Abstract

Summary

GlobalData, the industry analysis specialist, has released its new report, "Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global depression therapeutics market. The report identifies the key trends shaping and driving the global depression market. The report also provides insights in to the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights in to the pipeline products within the global depression market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData valued the global depression therapeutics market at $4.6 billion in 2010, and expects it to grow at a compound annual growth rate (CAGR) of 3.2% over the next seven years to reach $10.9 billion by 2018. The depression therapeutics market will witness the patent expiry of Lexapro in 2012, Cymbalta in 2013 and Effexor XR in 2014. However, the launch of new drugs such as Viibryd, LuAA21004, Levomilnacipran (F2695) and AGO178 (in the US), offering better efficacy and safety profiles, along with disease modifying properties, will help to sustain steady and positive growth during the forecast period to 2018.

Scope

The report provides information on the key drivers and challenges of the depression market. Its scope includes -

  • Annualized global depression market revenues data from 2005 to 2010, forecast for eight years to 2018.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Glutamate receptor which includes Metabotropic glutamate receptors 2 antagonist, Glutamate receptor 2 and 3 antagonist, Group II metabotropic glutamate receptors antagonist, Metabotropic glutamate receptor 5 antagonist, N-methyl d-aspartate receptor (NMDAR) antagonist, Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) potentiator whereas Seretonin receptor modulators which includes 5-HT3, 5-HT7 and 5-HT1A receptor receptor agonist and 5-HT transporter inhibitor, 5-HT3 and 5-HT2C antagonist, 5HT reuptake blockade, 5HT2 agonism, 5HT1A agonism, and 5HT1D central receptors agonist, 5-HT2A/5-HT2C/D2/D3 receptor antagonist followed by Triple-reuptake inhibitors, Monoamine oxidase (MAO) modulators, Arginine vasopressin antagonists and so on.
  • Analysis of the current and future competition in the global depression market. Key market players covered are Otsuka Holdings Co., Ltd, Forest Laboratories, H Lundbeck A/s, Eli Lilly, Targacept Inc., Fabre-Kramer Pharmaceuticals, Inc., Euthymics Bioscience, Inc., AstraZeneca PLC, and Novartis/Servier.
  • An insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the depression therapeutics market.
  • Analysis of key recent licensing and partnership agreements in the depression therapeutics market.

Reasons to buy

The report will enhance your decision making capabilities. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global depression market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global depression market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potential strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global depression market landscape? - Identify, understand and capitalize.

Table of contents

1. Table of contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2. Depression Therapeutics - Introduction

  • 2.1 Disease Overview
  • 2.2 Epidemiology
  • 2.3 Etiology and Pathophysiology
  • 2.4 Signs and Symptoms
  • 2.5 Diagnosis
  • 2.6 Treatment and Management Options
    • 2.6.1 Referral Pathway
  • 2.7 GlobalData Pipeline Report Guidance

3. Depression Therapeutics - Market Characterization

  • 3.1 Overview
  • 3.2 Depression Therapeutics Market Size (2005-2010) - Global
  • 3.3 Depression Therapeutics Market Forecast (2010-2018) - Global
  • 3.4 Depression Therapeutics Market Size (2005-2010) - The US
  • 3.5 Depression Therapeutics Market Forecast (2010-2018) - The US
  • 3.6 Depression Therapeutics Market Size (2005-2010) - France
  • 3.7 Depression Therapeutics Market Forecast (2010-2018) - France
  • 3.8 Depression Therapeutics Market Size (2005-2010) - Germany
  • 3.9 Depression Therapeutics Market Forecast (2010-2018) - Germany
  • 3.10 Depression Therapeutics Market Size (2005-2010) - Italy
  • 3.11 Depression Therapeutics Market Forecast (2010-2018) - Italy
  • 3.12 Depression Therapeutics Market Size (2005-2010) - Spain
  • 3.13 Depression Therapeutics Market Forecast (2010-2018) - Spain
  • 3.14 Depression Therapeutics Market Size (2005-2010) - The UK
  • 3.15 Depression Therapeutics Market Forecast (2010-2018) - The UK
  • 3.16 Depression Therapeutics Market Size (2005-2010) - Japan
  • 3.17 Depression Therapeutics Market Forecast (2010-2018) - Japan
  • 3.18 Drivers and Barriers for the Depression Therapeutics Market
    • 3.18.1 Drivers for the Depression Therapeutics Market
    • 3.18.2 Barriers for the Depression Therapeutics Market
  • 3.19 Opportunity and Unmet Need Analysis
  • 3.20 Key Takeaway

4. Depression Therapeutics: Competitive Assessment

  • 4.1 Overview
    • 4.1.1 Strategic Competitor Assessment
  • 4.2 Product Profiles for the Major Marketed Products in the Depression Therapeutics Market
    • 4.2.1 Selective Serotonin Reuptake Inhibitors (SSRIs)
    • 4.2.2 Lexapro (escitalopram)
    • 4.2.3 Viibryd (vilazodone hydrochloride)
    • 4.2.4 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
    • 4.2.5 Cymbalta (duloxetine hydrochloride)
    • 4.2.6 Pristiq (desvenlafaxine succinate)
    • 4.2.7 Symbyax (olanzapine and fluoxetine combination)
  • 4.3 Key Takeaway

5. Depression Therapeutics - Pipeline Assessment

  • 5.1 Overview
  • 5.2 Strategic Pipeline Assessment
  • 5.3 Depression Therapeutics Pipeline - Pipeline by Phases of Development
    • 5.3.1 Depression Therapeutics - Phase III Pipeline
    • 5.3.2 Depression Therapeutics - Phase II Pipeline
    • 5.3.3 Depression Therapeutics - Phase I Pipeline
    • 5.3.4 Depression Market - Pre-Clinical Pipeline
    • 5.3.5 Technology Trends Analytic Framework
  • 5.4 Depression Therapeutics Market -Pipeline by Mechanism of Action
  • 5.5 Depression Therapeutics - Promising Drugs under Clinical Development
  • 5.6 Molecule Profile for Promising Drugs Under Clinical Development
    • 5.6.1 Lu AA21004
    • 5.6.2 TC-5214
    • 5.6.3 AGO178 (agomelatine)
  • 5.7 Key Takeaway

6. Depression Therapeutics - Clinical Trials Mapping

  • 6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
  • 6.2 Clinical Trials by Phase
  • 6.3 Clinical Trials by Trial Status
  • 6.4 Prominent Sponsors
  • 6.5 Top Companies Participating in Depression Therapeutics Clinical Trials

7. Strategic Assessment

  • 7.1 Key Events Impacting the Future Market
  • 7.2 Depression Therapeutics: Implications for Future Market Competition

8. Depression Therapeutics: Future Players

  • 8.1 Introduction
  • 8.2 Company Profiles
    • 8.2.1 Lundbeck A/S
    • 8.2.2 Novartis AG
    • 8.2.3 AstraZeneca PLC
    • 8.2.4 Eli Lilly and Company
    • 8.2.5 Targacept Inc.

9. Depression Therapeutics - Licensing and Partnership Deals

10. Depression Therapeutics - Appendix

  • 10.1 Market Definitions
  • 10.2 Abbreviations
  • 10.3 Methodology
    • 10.3.1 Coverage
    • 10.3.2 Secondary Research
    • 10.3.3 Forecasting
    • 10.3.4 Primary Research
    • 10.3.5 Expert Panel Validation
  • 10.4 Contact Us
  • 10.5 Disclaimer
  • 10.6 Bibliography

List of Tables
  • Table 1: Stages of Depression
  • Table 2: Depression Therapeutics Market, Global, Revenue ($bn), 2005-2010
  • Table 3: Depression Therapeutics Market, Global, Forecast ($bn), 2010-2018
  • Table 4: Depression Therapeutics Market, The US, Revenue ($m), 2005-2010
  • Table 5: Depression Therapeutics Market, The US, Forecast ($m), 2010-2018
  • Table 6: Depression Therapeutics Market, France, Revenue ($m), 2005-2010
  • Table 7: Depression Therapeutics Market, France, Forecast ($m), 2010-2018
  • Table 8: Depression Therapeutics Market, Germany, Revenue ($m), 2005-2010
  • Table 9: Depression Therapeutics Market, Germany, Forecast ($m), 2010-2018
  • Table 10: Depression Therapeutics Market, Italy, Revenue ($m), 2005-2010
  • Table 11: Depression Therapeutics Market, Italy, Forecast ($m), 2010-2018
  • Table 12: Depression Therapeutics Market, Spain, Revenue ($m), 2005-2010
  • Table 13: Depression Therapeutics Market, Spain, Forecast ($m), 2010-2018
  • Table 14: Depression Therapeutics Market, The UK, Revenue ($m), 2005-2010
  • Table 15: Depression Therapeutics Market, The UK, Forecast ($m), 2010-2018
  • Table 16: Depression Therapeutics Market, Japan, Revenue ($m), 2005-2010
  • Table 17: Depression Therapeutics Market, Japan, Forecast ($m), 2010-2018
  • Table 18: SSRIs Approved for Depression
  • Table 19: Summary of Results for the Primary Efficacy Endpoint
  • Table 20: SNRIs Approved for Depression
  • Table 21: MADRS Total Score Mean Change from Baseline to Endpoint
  • Table 22: Depression Therapeutics, Phase III Pipeline, 2011
  • Table 23: Depression Therapeutics, Phase II Pipeline, 2011
  • Table 24: Depression Therapeutics, Phase I Pipeline, 2011
  • Table 25: Depression Therapeutics, Pre-clinical Pipeline, 2011
  • Table 26: Depression Therapeutics - Most Promising Drugs Under Clinical Development, 2011
  • Table 27: Lu AA21004 Efficacy Measure
  • Table 28: Treatment-Related Adverse Events
  • Table 29: AGO178, Active Comparator Study
  • Table 30: Depression Therapeutics, Clinical Trials by Country, 2011
  • Table 31: Depression Therapeutics, Clinical Trials by Phase, 2011
  • Table 32: Depression Therapeutics, Clinical Trials by Status, 2011
  • Table 33: Depression Therapeutics, Overall Sponsors, 2011
  • Table 34: Depression Therapeutics, Prominent Sponsors, 2011
  • Table 35: Depression Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
  • Table 36: Lundbeck A/S - Depression, Pipeline Products, 2011
  • Table 37: Novartis, Depression Pipeline, 2011
  • Table 38: AstraZeneca PLC, Depression Pipeline, 2011
  • Table 39: Eli Lilly and Company, Depression Pipeline, 2011
  • Table 40: Targacept Inc., Depression Pipeline, 2011
  • Table 41: Depression Therapeutics, Global, Deals, 2009-2011

List of Figures
  • Figure 1: DSM-IV Diagnostic Criteria for Depression
  • Figure 2: Total Estimated Cost of Brain Disorders in Europe by Disease Area
  • Figure 3: Economic Burden Associated with Depression
  • Figure 4: Relationship Between Major Depression and Cardiovascular Disease
  • Figure 5: Serotonergic Systems in Alteration of Depression
  • Figure 6: Alterations of Noradrenergic Systems in Depression
  • Figure 7: Alterations of Dopaminergic Systems in Depression
  • Figure 8: Diagnostic Approach for Depression
  • Figure 9: Drug Classes for the Treatment of Depression
  • Figure 10: Treatment Algorithm
  • Figure 11: Referral Pathway for Depression
  • Figure 12: Depression Therapeutics Market, Global, Revenue ($bn), 2005-2010
  • Figure 13: Depression Therapeutics Market, Global, Forecast ($bn), 2010-2018
  • Figure 14: Depression Therapeutics Market, The US, Revenue ($m), 2005-2010
  • Figure 15: Depression Therapeutics Market, The US, Forecast ($m), 2010-2018
  • Figure 16: Depression Therapeutics Market, France, Revenue ($m), 2005-2010
  • Figure 17: Depression Therapeutics Market, France, Forecast ($m), 2010-2018
  • Figure 18: Depression Therapeutics Market, Germany, Revenue ($m), 2005-2010
  • Figure 19: Depression Therapeutics Market, Germany, Forecast ($m), 2010-2018
  • Figure 20: Depression Therapeutics Market, Italy, Revenue ($m), 2005-2010
  • Figure 21: Depression Therapeutics Market, Italy, Forecast ($m), 2010-2018
  • Figure 22: Depression Therapeutics Market, Spain, Revenue ($m), 2005-2010
  • Figure 23: Depression Therapeutics Market, Spain, Forecast ($m), 2010-2018
  • Figure 24: Depression Therapeutics Market, The UK, Revenue ($m), 2005-2010
  • Figure 25: Depression Therapeutics Market, The UK, Forecast ($m), 2010-2018
  • Figure 26: Depression Therapeutics Market, Japan, Revenue ($m), 2005-2010
  • Figure 27: Depression Therapeutics Market, Japan, Forecast ($m), 2010-2018
  • Figure 28: Opportunity and Unmet Need in the Depression Therapeutics Market, 2010
  • Figure 29: Depression Therapeutics, Strategic Competitor Assessment, 2010
  • Figure 30: Depression Therapeutics, Pipeline by Phase of Development, 2011
  • Figure 31: Approaches to the Development of Antidepressants Targeting Non Monoaminergic Components
  • Figure 32: Depression Therapeutics, Technology Trends Analytical Framework, 2011
  • Figure 33: Depression Therapeutics, Technology Trends Analytical Framework, Description, 2011
  • Figure 34: Depression Therapeutics, Pipeline by Mechanism of Action (%), 2011
  • Figure 35: Depression Therapeutics, Clinical Trials by Country, 2011
  • Figure 36: Depression Therapeutics, Clinical Trials by Phase (%), 2011
  • Figure 37: Depression Therapeutics, Clinical Trials by Status (%), 2011
  • Figure 38: Depression Therapeutics, Overall Sponsors (%), 2011
  • Figure 39: Depression Therapeutics, Prominent Sponsors (%), 2011
  • Figure 40: Depression Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
  • Figure 41: Depression Therapeutics Market, Drivers and Barriers, 2011
  • Figure 42: Implications for Future Market Competition in the Depression Market, 2011
  • Figure 43: Depression Therapeutics Market - Pipeline by Company, 2011
  • Figure 44: GlobalData Market Forecasting Model
Back to Top